Stock Market Reviews

TAK (Takeda Pharmaceutical Company Limited) News

Get the latest news, insights, and market updates on TAK (Takeda Pharmaceutical Company Limited). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• A Look at Innovent Biologics (SEHK:1801) Valuation After Strategic Global Partnership With Takeda
  Innovent Biologics (SEHK:1801) just unveiled a partnership with Takeda to speed up global development and commercialization of next-generation cancer therapies. The collaboration features profit-sharing, milestone payments, and expanded international reach. See our latest analysis for Innovent Biologics. Innovent’s latest alliance with Takeda has arrived following strong momentum, with the company’s share price delivering an exceptional 141% year-to-date gain. Recent special investor calls...
  Oct 27, 2025 - $TAK
• Takeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls
  The deals will bolster Takeda’s ADC portfolio, which the company now considers a key modality focus within its oncology business.
  Oct 23, 2025 - $TAK
• Stifel Canada on Healwell AI's Darwen Platform
  Healwell AI (AIDX.TO) this week, in collaboration with vedolizumab manufacturer, Takeda, presented n
  Oct 22, 2025 - $TAK
• Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
  Innovent Biologics (HKEX: 01801) announced a strategic global collaboration with Takeda (TSE:4502, NYSE:TAK) to advance next-generation IO and ADC cancer therapies, with the goal of developing potentially transformative cancer treatments to benefit patients worldwide.
  Oct 22, 2025 - $TAK
• Takeda stakes more than $11B on cancer drugs from China
  The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be “transformative” for its oncology portfolio.
  Oct 22, 2025 - $TAK
• Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight
  DelveInsight's Glomerulonephritis Market Insights report includes a comprehensive understanding of current treatment practices, glomerulonephritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
  Oct 22, 2025 - $TAK
• Health Care Roundup: Market Talk
  HEALTH NEWS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0757 GMT – The muted response to Innovent’s cancer-drug deal with Takeda looks like a buying opportunity to Citi analysts.
  Oct 22, 2025 - $TAK
• China’s Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion
  The tie-up is the latest between Chinese companies and international pharma majors looking to expand their global reach and tap promising drug pipelines developing in China.
  Oct 22, 2025 - $TAK